Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).

Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taïeb A, Owen R, Putnam W, Castro M, DeBusk K, Lin CY, Voulgari A, Yen K, Omachi TA.

J Am Acad Dermatol. 2018 May;78(5):863-871.e11. doi: 10.1016/j.jaad.2018.01.017. Epub 2018 Jan 17.

2.

Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.

Casale TB, Chipps BE, Rosén K, Trzaskoma B, Haselkorn T, Omachi TA, Greenberg S, Hanania NA.

Allergy. 2018 Feb;73(2):490-497. doi: 10.1111/all.13302. Epub 2017 Sep 23.

3.

Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria.

Saini SS, Omachi TA, Trzaskoma B, Hulter HN, Rosén K, Sterba PM, Courneya JP, Lackey A, Chen H.

J Invest Dermatol. 2017 Apr;137(4):958-961. doi: 10.1016/j.jid.2016.11.025. Epub 2016 Dec 6. No abstract available. Erratum in: J Invest Dermatol. 2019 Feb;139(2):496-497.

4.

Corticosteroid-related toxicity in patients with chronic idiopathic urticariachronic spontaneous urticaria.

Ledford D, Broder MS, Antonova E, Omachi TA, Chang E, Luskin A.

Allergy Asthma Proc. 2016 Nov;37(6):458-465.

PMID:
27931301
5.

A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.

Ledford D, Busse W, Trzaskoma B, Omachi TA, Rosén K, Chipps BE, Luskin AT, Solari PG.

J Allergy Clin Immunol. 2017 Jul;140(1):162-169.e2. doi: 10.1016/j.jaci.2016.08.054. Epub 2016 Nov 5.

6.

Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis.

Luskin AT, Antonova EN, Broder MS, Chang EY, Omachi TA, Ledford DK.

Clinicoecon Outcomes Res. 2016 Oct 25;8:641-648. eCollection 2016.

7.

Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma.

Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G, Eisner MD, Chen H, Omachi TA, Farkouh ME, Rothman KJ.

J Allergy Clin Immunol. 2017 May;139(5):1489-1495.e5. doi: 10.1016/j.jaci.2016.07.038. Epub 2016 Sep 14.

8.

Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies.

Gimenéz-Arnau AM, Spector S, Antonova E, Trzaskoma B, Rosén K, Omachi TA, Stull D, Balp MM, Murphy T.

Clin Transl Allergy. 2016 Aug 18;6:32. doi: 10.1186/s13601-016-0120-0. eCollection 2016.

9.

Sleep Apnea and Obstructive Airway Disease in Older Men: Outcomes of Sleep Disorders in Older Men Study.

Zhao YY, Blackwell T, Ensrud KE, Stone KL, Omachi TA, Redline S; Osteoporotic Fractures in Men (MrOS) Study Group.

Sleep. 2016 Jul 1;39(7):1343-51. doi: 10.5665/sleep.5960.

10.

Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.

Kaplan A, Ferrer M, Bernstein JA, Antonova E, Trzaskoma B, Raimundo K, Rosén K, Omachi TA, Khalil S, Zazzali JL.

J Allergy Clin Immunol. 2016 Feb;137(2):474-81. doi: 10.1016/j.jaci.2015.08.023. Epub 2015 Oct 21.

11.

Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use.

Zazzali JL, Broder MS, Omachi TA, Chang E, Sun GH, Raimundo K.

Allergy Asthma Proc. 2015 Jul-Aug;36(4):268-74. doi: 10.2500/aap.2015.36.3863.

PMID:
26108084
12.

Asthma exacerbations and lung function in patients with severe or difficult-to-treat asthma.

Calhoun WJ, Haselkorn T, Miller DP, Omachi TA.

J Allergy Clin Immunol. 2015 Oct;136(4):1125-7.e4. doi: 10.1016/j.jaci.2015.05.014. Epub 2015 Jun 20. No abstract available.

PMID:
26104221
13.

Risk adjustment for health care financing in chronic disease: what are we missing by failing to account for disease severity?

Omachi TA, Gregorich SE, Eisner MD, Penaloza RA, Tolstykh IV, Yelin EH, Iribarren C, Dudley RA, Blanc PD.

Med Care. 2013 Aug;51(8):740-7. doi: 10.1097/MLR.0b013e318298082f.

14.

Trends in on-label and off-label modafinil use in a nationally representative sample.

Peñaloza RA, Sarkar U, Claman DM, Omachi TA.

JAMA Intern Med. 2013 Apr 22;173(8):704-6. doi: 10.1001/jamainternmed.2013.2807. No abstract available.

PMID:
23552641
15.

Lower health literacy is associated with poorer health status and outcomes in chronic obstructive pulmonary disease.

Omachi TA, Sarkar U, Yelin EH, Blanc PD, Katz PP.

J Gen Intern Med. 2013 Jan;28(1):74-81. doi: 10.1007/s11606-012-2177-3. Epub 2012 Aug 14.

16.

Both pulmonary and extra-pulmonary factors predict the development of disability in chronic obstructive pulmonary disease.

Singer JP, Katz PP, Iribarren C, Omachi TA, Sanchez G, Yelin EH, Cisternas MG, Blanc PD.

Respiration. 2013;85(5):375-83. doi: 10.1159/000338110. Epub 2012 Jun 9.

17.
18.

Relationship of obesity with respiratory symptoms and decreased functional capacity in adults without established COPD.

Zutler M, Singer JP, Omachi TA, Eisner M, Iribarren C, Katz P, Blanc PD.

Prim Care Respir J. 2012 Jun;21(2):194-201. doi: 10.4104/pcrj.2012.00028.

19.

Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes.

Omachi TA, Blanc PD, Claman DM, Chen H, Yelin EH, Julian L, Katz PP.

Sleep Med. 2012 May;13(5):476-83. doi: 10.1016/j.sleep.2011.12.007. Epub 2012 Mar 18.

20.

Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency.

Omachi TA, Eisner MD, Rames A, Markovtsova L, Blanc PD.

Respir Res. 2011 Mar 23;12:35. doi: 10.1186/1465-9921-12-35.

21.

Evaluating quality of life in patients with asthma and rhinitis: English adaptation of the rhinasthma questionnaire.

Chen H, Cisternas MG, Katz PP, Omachi TA, Trupin L, Yelin EH, Balmes JR, Blanc PD.

Ann Allergy Asthma Immunol. 2011 Feb;106(2):110-118.e1. doi: 10.1016/j.anai.2010.10.027. Epub 2011 Jan 8.

22.

The role of physical inactivity in increasing disability among older adults with obstructive airway disease.

Katz P, Chen H, Omachi TA, Gregorich SE, Julian L, Cisternas M, Balmes J, Blanc PD.

J Cardiopulm Rehabil Prev. 2011 May-Jun;31(3):193-7. doi: 10.1097/HCR.0b013e3181fc09b7.

23.

Development of disability in chronic obstructive pulmonary disease: beyond lung function.

Eisner MD, Iribarren C, Blanc PD, Yelin EH, Ackerson L, Byl N, Omachi TA, Sidney S, Katz PP.

Thorax. 2011 Feb;66(2):108-14. doi: 10.1136/thx.2010.137661. Epub 2010 Nov 3.

24.

Influence of anxiety on health outcomes in COPD.

Eisner MD, Blanc PD, Yelin EH, Katz PP, Sanchez G, Iribarren C, Omachi TA.

Thorax. 2010 Mar;65(3):229-34. doi: 10.1136/thx.2009.126201.

25.

Measurement of COPD severity using a survey-based score: validation in a clinically and physiologically characterized cohort.

Eisner MD, Omachi TA, Katz PP, Yelin EH, Iribarren C, Blanc PD.

Chest. 2010 Apr;137(4):846-51. doi: 10.1378/chest.09-1855. Epub 2009 Dec 29.

26.

The impact of disability on depression among individuals with COPD.

Katz PP, Julian LJ, Omachi TA, Gregorich SE, Eisner MD, Yelin EH, Blanc PD.

Chest. 2010 Apr;137(4):838-45. doi: 10.1378/chest.09-1939. Epub 2009 Nov 20.

27.

Socioeconomic status, race and COPD health outcomes.

Eisner MD, Blanc PD, Omachi TA, Yelin EH, Sidney S, Katz PP, Ackerson LM, Sanchez G, Tolstykh I, Iribarren C.

J Epidemiol Community Health. 2011 Jan;65(1):26-34. doi: 10.1136/jech.2009.089722. Epub 2009 Oct 23.

28.

The COPD Helplessness Index: a new tool to measure factors affecting patient self-management.

Omachi TA, Katz PP, Yelin EH, Iribarren C, Knight SJ, Blanc PD, Eisner MD.

Chest. 2010 Apr;137(4):823-30. doi: 10.1378/chest.09-0764. Epub 2009 Oct 16.

29.

Poor outcomes and asthma hospitalisations: How important is asthma severity and how do we measure it?

Omachi TA.

Allergol Immunopathol (Madr). 2009 Sep-Oct;37(5):223-4. doi: 10.1016/j.aller.2009.06.007. No abstract available.

30.

Depression and health-related quality of life in chronic obstructive pulmonary disease.

Omachi TA, Katz PP, Yelin EH, Gregorich SE, Iribarren C, Blanc PD, Eisner MD.

Am J Med. 2009 Aug;122(8):778.e9-15. doi: 10.1016/j.amjmed.2009.01.036.

31.

Obstructive sleep apnea: a risk factor for work disability.

Omachi TA, Claman DM, Blanc PD, Eisner MD.

Sleep. 2009 Jun;32(6):791-8.

32.

The COPD severity score: a dynamic prediction tool for health-care utilization.

Omachi TA, Yelin EH, Katz PP, Blanc PD, Eisner MD.

COPD. 2008 Dec;5(6):339-46. doi: 10.1080/15412550802522700.

33.

Risk factors for death in adults with severe asthma.

Omachi TA, Iribarren C, Sarkar U, Tolstykh I, Yelin EH, Katz PP, Blanc PD, Eisner MD.

Ann Allergy Asthma Immunol. 2008 Aug;101(2):130-6. doi: 10.1016/S1081-1206(10)60200-1.

34.

SynopSIS: integrating physician sign-out with the electronic medical record.

Sarkar U, Carter JT, Omachi TA, Vidyarthi AR, Cucina R, Bokser S, van Eaton E, Blum M.

J Hosp Med. 2007 Sep;2(5):336-42.

PMID:
17935249

Supplemental Content

Loading ...
Support Center